A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
Public ClinicalTrials.gov record NCT01470313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE)
Study identification
- NCT ID
- NCT01470313
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Interventions
- PD-0360324 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2011
- Primary completion
- Oct 31, 2013
- Completion
- Oct 31, 2013
- Last update posted
- Jan 28, 2014
2011 – 2013
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Anniston | Alabama | 36207 | — |
| Pfizer Investigational Site | Oxford | Alabama | 36203 | — |
| Pfizer Investigational Site | Los Angeles | California | 90045 | — |
| Pfizer Investigational Site | Orange Park | Florida | 32073 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60611 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46256 | — |
| Pfizer Investigational Site | Fort Gratiot | Michigan | 48059 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28210 | — |
| Pfizer Investigational Site | Ducansville | Pennsylvania | 16635 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Pfizer Investigational Site | Wyomissing | Pennsylvania | 19610 | — |
| Pfizer Investigational Site | Rapid City | South Dakota | 57701 | — |
| Pfizer Investigational Site | Rapid City | South Dakota | 57702 | — |
| Pfizer Investigational Site | Jackson | Tennessee | 38305 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | Norfolk | Virginia | 23507 | — |
| Pfizer Investigational Site | Clarksburg | West Virginia | 26301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01470313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01470313 live on ClinicalTrials.gov.